Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	DAUNORUBICIN HYDROCHLORIDE	daunorubicin hydrochloride	INJECTABLE;INJECTION	050731	NDA	Hikma Pharmaceuticals USA Inc.	0143-9550-01	1 VIAL in 1 CARTON (0143-9550-01) / 10 mL in 1 VIAL	2018-01-02
Hikma	DAUNORUBICIN HYDROCHLORIDE	daunorubicin hydrochloride	INJECTABLE;INJECTION	050731	NDA	Hikma Pharmaceuticals USA Inc.	0143-9551-10	10 VIAL in 1 BOX (0143-9551-10) / 4 mL in 1 VIAL (0143-9551-01)	2018-01-02
Hisun Pharm Hangzhou	DAUNORUBICIN HYDROCHLORIDE	daunorubicin hydrochloride	INJECTABLE;INJECTION	208759	ANDA	Hisun Pharmaceuticals USA, Inc.	42658-019-01	1 VIAL in 1 BOX (42658-019-01) / 10 mL in 1 VIAL	2020-01-20
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

WHAT IS DAUNORUBICIN HYDROCHLORIDE?

Daunorubicin hydrochloride is an anthracycline antibiotic used in the treatment of certain types of cancer, primarily acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). It functions by intercalating into DNA and inhibiting topoisomerase II, thereby disrupting DNA replication and transcription in rapidly dividing cancer cells. The drug is administered intravenously.

PRIMARY MANUFACTURERS AND SUPPLIERS

The production of daunorubicin hydrochloride is a complex process, often involving fermentation and subsequent chemical synthesis. The market is served by a limited number of global manufacturers.

Pfizer Inc.: Historically a major producer and marketer of daunorubicin hydrochloride under the brand name Cerubidine. While Pfizer's role in direct manufacturing may have evolved, it remains a significant entity in the supply chain through its established product lines and global distribution networks.
Accord Healthcare Ltd.: A global pharmaceutical company that manufactures and supplies generic daunorubicin hydrochloride. Accord Healthcare emphasizes its role in providing affordable and accessible chemotherapy agents.
Fresenius Kabi AG: A global healthcare company that supplies a range of injectable drugs, including generic daunorubicin hydrochloride. Fresenius Kabi focuses on hospital and infusion therapies.
Teva Pharmaceutical Industries Ltd.: A large generic pharmaceutical manufacturer that offers daunorubicin hydrochloride. Teva's extensive portfolio includes oncology drugs, contributing to its presence in this market.
Bristol Myers Squibb Company: Another major pharmaceutical company with a history of developing and marketing chemotherapy agents. While their current direct manufacturing capacity for daunorubicin hydrochloride might have shifted, their historical involvement and potential licensing agreements are relevant.

ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURERS

The synthesis of daunorubicin hydrochloride API is a specialized area, often requiring significant expertise in fermentation and natural product chemistry. Key API suppliers include:

Beijing Biocides Co., Ltd.: A Chinese-based manufacturer specializing in pharmaceutical intermediates and APIs, including anthracycline derivatives.
Sichuan Kelun Pharmaceutical Co., Ltd.: A prominent Chinese pharmaceutical company that manufactures APIs for a range of therapeutic areas, including oncology.
Sun Pharmaceutical Industries Ltd.: While primarily known for finished dosage forms, Sun Pharma is a major global API producer. They may supply daunorubicin hydrochloride API or key intermediates.
Novartis AG: Through its internal manufacturing capabilities or its subsidiaries, Novartis is a potential supplier of high-quality daunorubicin hydrochloride API, given its extensive oncology drug development and manufacturing infrastructure.

REGULATORY LANDSCAPE AND QUALITY STANDARDS

The production of daunorubicin hydrochloride is subject to stringent regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with Good Manufacturing Practices (GMP) is mandatory.

FDA Approval: Drug products containing daunorubicin hydrochloride must receive FDA approval for marketing in the United States. This involves rigorous review of safety, efficacy, and manufacturing processes.
EMA Certification: Similarly, drugs must obtain a marketing authorization from the EMA for distribution within the European Union. This includes site inspections and quality assessments of manufacturing facilities.
ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines are followed to ensure global quality standards.
Pharmacopeial Standards: Daunorubicin hydrochloride must meet the specifications outlined in major pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.).

SUPPLY CHAIN CONSIDERATIONS

The supply chain for daunorubicin hydrochloride involves several critical stages, from API synthesis to finished drug product formulation and distribution.

Raw Material Sourcing: The initial stages of daunorubicin production involve sourcing specific microbial strains for fermentation or precursor chemicals for synthesis. The quality and consistency of these raw materials are paramount.
Fermentation and Isolation: Daunorubicin is typically produced through the fermentation of Streptomyces species. The subsequent isolation and purification of the active compound require specialized techniques.
Chemical Synthesis and Salt Formation: The isolated daunorubicin is then chemically modified and converted into its hydrochloride salt form to improve stability and solubility for pharmaceutical use.
Formulation and Lyophilization: The daunorubicin hydrochloride API is formulated into the final dosage form, often a lyophilized powder for injection, requiring sterile manufacturing environments.
Packaging and Distribution: The finished product is packaged in vials and distributed under controlled conditions to hospitals and clinics. Cold chain management may be necessary depending on product stability.

PATENTS AND INTELLECTUAL PROPERTY

While the original patents for daunorubicin have long expired, intellectual property relevant to its production and formulation may still exist.

Process Patents: Companies may hold patents on novel or improved methods of synthesizing daunorubicin hydrochloride API, increasing yield, purity, or reducing manufacturing costs.
Formulation Patents: Innovations in drug delivery or formulation, such as improved stability or specific lyophilization techniques, can be patented.
Exclusivity Periods: For generic versions, manufacturers must navigate patent cliffs and any potential market exclusivity granted to innovator drugs.

MARKET TRENDS AND DEMAND DRIVERS

The demand for daunorubicin hydrochloride is primarily driven by the incidence of leukemia and related hematological malignancies.

Cancer Incidence Rates: Global increases in cancer diagnoses, particularly leukemia, directly influence the demand for chemotherapeutic agents like daunorubicin hydrochloride.
Generic Competition: The availability of generic daunorubicin hydrochloride has increased market access and potentially lowered prices, but also intensified competition among suppliers.
Therapeutic Guidelines: Inclusion in established treatment protocols and clinical guidelines for AML and ALL underpins consistent demand.
Development of New Therapies: While daunorubicin remains a standard of care, the emergence of novel targeted therapies and immunotherapies for leukemia could indirectly impact its long-term market share, though it is often used in combination regimens.

KEY COMPETITORS AND STRATEGIC MOVES

The competitive landscape is characterized by a mix of established pharmaceutical giants and specialized generic manufacturers.

Pfizer: While historically dominant, Pfizer's strategy has shifted towards newer oncology drugs. However, their legacy product remains a reference point for quality.
Generic Manufacturers (Accord, Teva, Fresenius Kabi): These companies focus on efficient, high-volume production and competitive pricing. Strategic moves often involve expanding their global reach and obtaining regulatory approvals in new markets.
API Suppliers (Beijing Biocides, Sichuan Kelun): These suppliers' strategies center on cost-effectiveness, scale of production, and adherence to international quality standards to secure contracts with finished drug product manufacturers.

PRICING AND AFFORDABILITY

Pricing for daunorubicin hydrochloride can vary significantly based on factors such as:

Manufacturer: Branded versus generic products.
Region: Market access and reimbursement policies in different countries.
Volume: Bulk purchasing agreements.
Supply Chain Costs: Manufacturing, regulatory compliance, and distribution expenses.

Generic availability has generally led to more affordable treatment options, a critical factor in cancer therapy access.

EMERGING MARKETS AND OPPORTUNITIES

Developing markets represent significant growth opportunities due to increasing healthcare infrastructure and rising cancer incidence.

Asia-Pacific: Countries like India and China are not only growing API producers but also expanding markets for finished pharmaceutical products.
Latin America: Increasing investment in healthcare and a growing middle class are driving demand for advanced medical treatments.
Africa: Efforts to improve access to essential medicines, including chemotherapy, present long-term opportunities.

Suppliers focusing on navigating local regulatory pathways and establishing robust distribution networks in these regions are positioned for success.

FUTURE OUTLOOK

The demand for daunorubicin hydrochloride is expected to remain stable in the near to medium term, supported by its established role in leukemia treatment. However, the long-term outlook may be influenced by the continued development of more targeted and potentially less toxic therapies. Suppliers will need to focus on cost optimization, quality assurance, and global supply chain resilience to maintain their market position. Innovations in manufacturing processes that enhance efficiency and reduce environmental impact could also become a competitive differentiator.

Key Takeaways

Daunorubicin hydrochloride production is concentrated among a limited number of global pharmaceutical companies and API manufacturers.
Stringent regulatory compliance, including GMP and pharmacopeial standards, is critical for all suppliers.
The supply chain involves complex fermentation and chemical synthesis processes, demanding specialized expertise.
While original patents have expired, process and formulation patents may still influence market dynamics.
Demand is driven by leukemia incidence, with generic competition impacting pricing and accessibility.
Emerging markets offer significant growth potential for suppliers.

FAQs

1. Who are the primary manufacturers of finished daunorubicin hydrochloride drug products?

The primary manufacturers of finished daunorubicin hydrochloride drug products include Accord Healthcare Ltd., Fresenius Kabi AG, and Teva Pharmaceutical Industries Ltd. Historically, Pfizer Inc. was also a major producer.

2. What are the main regulatory bodies overseeing daunorubicin hydrochloride production?

The main regulatory bodies overseeing daunorubicin hydrochloride production are the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with ICH guidelines and major pharmacopeial standards is also mandatory.

3. Are there any ongoing patent disputes related to daunorubicin hydrochloride manufacturing?

While the core patents for daunorubicin have expired, disputes could arise related to specific novel manufacturing processes, formulation enhancements, or polymorphs if newer intellectual property is involved. A detailed patent landscape analysis would be required to confirm specific active disputes.

4. How does the cost of daunorubicin hydrochloride API impact the final drug product pricing?

The cost of daunorubicin hydrochloride API is a significant component of the overall cost of the finished drug product. Fluctuations in API pricing due to raw material availability, manufacturing efficiency, or supplier competition directly influence the pricing of the injectable medication.

5. What are the main challenges for new suppliers entering the daunorubicin hydrochloride market?

New suppliers face challenges in achieving the high levels of quality and regulatory compliance required by health authorities, establishing robust and reliable supply chains for both API and finished product, securing market access through regulatory approvals, and competing with established players on price and established customer relationships.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approval Process. Retrieved from [FDA Website] (Note: Specific URL varies; general reference to FDA's regulatory framework). [2] European Medicines Agency. (n.d.). How we authorise medicines. Retrieved from [EMA Website] (Note: Specific URL varies; general reference to EMA's authorization process). [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website] (Note: Specific URL varies; general reference to ICH guidelines). [4] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from [USP Website] (Note: Access to specific monographs requires subscription; general reference to pharmacopeial standards). [5] European Pharmacopoeia. (n.d.). Ph. Eur. Online. Retrieved from [EDQM Website] (Note: Access to specific monographs requires subscription; general reference to pharmacopeial standards).

Suppliers and packagers for DAUNORUBICIN HYDROCHLORIDE

DAUNORUBICIN HYDROCHLORIDE

DAUNORUBICIN HYDROCHLORIDE SUPPLIER LANDSCAPE